Skip to main content
SpringerLink
Log in

Reply to “At what price decreased mortality risk?”

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ong KL, Beall DP, Frohbergh M, Lau E, Hirsch JA (2018) Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? Osteoporos Int 29(2):375–383

    Article  PubMed  CAS  Google Scholar 

  2. Hirsch JA, Chandra RV, Pampati V, Barr JD, Brook AL, Manchikanti L (2016) Analysis of vertebral augmentation practice patterns: a 2016 update. J Neurointerv Surg 8:1299–1304

    Article  PubMed  Google Scholar 

  3. Edidin AA, Ong KL, Lau E, Schmier JK, Kemner JE, Kurtz SM (2012) Cost-effectiveness analysis of treatments for vertebral compression fractures. Appl Health Econ Health Policy 10(4):273–284

    Article  PubMed  Google Scholar 

  4. Ong KL, Lau E, Kemner JE, Kurtz SM (2013) Two-year cost comparison of vertebroplasty and kyphoplasty for the treatment of vertebral compression fractures: are initial surgical costs misleading? Osteoporos Int 24(4):1437–1445

    Article  PubMed  CAS  Google Scholar 

  5. Lau E, Ong K, Kurtz S, Schmier J, Edidin A (2008) Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am 90(7):1479–1486

    Article  PubMed  Google Scholar 

  6. Chen AT, Cohen DB, Skolasky RL (2013) Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. J Bone Joint Surg Am 95(19):1729–1736

    Article  PubMed  Google Scholar 

  7. Edidin AA, Ong KL, Lau E, Kurtz SM (2011) Mortality risk for operated and nonoperated vertebral fracture patients in the medicare population. J Bone Miner Res 26(7):1617–1626

    Article  PubMed  Google Scholar 

  8. Edidin AA, Ong KL, Lau E, Kurtz SM (2015) Morbidity and mortality after vertebral fractures: comparison of vertebral augmentation and nonoperative Management in the Medicare Population. Spine (Phila Pa 1976) 40(15):1228–1241

    Article  Google Scholar 

  9. Lange A, Kasperk C, Alvares L, Sauermann S, Braun S (2014) Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data. Spine (Phila Pa 1976) 39(4):318–326

    Article  Google Scholar 

  10. McCullough BJ, Comstock BA, Deyo RA, Kreuter W, Jarvik JG (2013) Major medical outcomes with spinal augmentation vs conservative therapy. JAMA Intern Med 173(16):1514–1521

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Exponent received funding from Medtronic for this study.

Author information

Authors and Affiliations

  1. Exponent, Inc., 3440 Market St, Suite 600, Philadelphia, PA, 19104, USA

    K.L. Ong & M. Frohbergh

  2. Oklahoma Spine, Edmond, OK, USA

    D.P. Beall

  3. Exponent, Inc., Menlo Park, CA, USA

    E. Lau

  4. Massachusetts General Hospital, Boston, MA, USA

    J.A. Hirsch

Authors
  1. K.L. Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D.P. Beall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Frohbergh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J.A. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K.L. Ong.

Ethics declarations

Financial disclosure/conflict of interest

KLO, EL, MF: employees of Exponent, Inc., a scientific and engineering consulting firm

KLO: Exponent has been paid fees by companies and suppliers for his consulting services on behalf of such companies and suppliers (Medtronic, Stryker Orthopaedics, Sanofi, Ferring Pharmaceuticals, Paradigm Spine, Pacira Pharmaceuticals, St. Jude Medical, Zimmer Biomet, Joerns Healthcare, SpineFrontier, Ethicon, DJO, Ossur)

JAH: direct consulting fees (Medtronic, Globus (one-time fee)); Codman Neurovascular Data and Safety Monitoring Board participation

DPB: Benvenue: paid consultant; paid presenter or speaker; stock or stock options

Lilly: paid presenter or speaker

Lilly, Amendia, Medtronic: board or committee member; paid consultant; research support; stock or stock options

Medtronic: paid presenter or speaker

SIR: board or committee member

Vexim: board or committee member; stock or stock options

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ong, K., Beall, D., Frohbergh, M. et al. Reply to “At what price decreased mortality risk?”. Osteoporos Int 29, 1929–1930 (2018). https://doi.org/10.1007/s00198-018-4551-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-018-4551-4

Search

Navigation